Effect of glycation inhibitors on aging and age-related diseases

Mech Ageing Dev. 2016 Dec:160:1-18. doi: 10.1016/j.mad.2016.09.006. Epub 2016 Sep 23.

Abstract

Vast evidence supports the view that glycation of proteins is one of the main factors contributing to aging and is an important element of etiopathology of age-related diseases, especially type 2 diabetes mellitus, cataract and neurodegenerative diseases. Counteracting glycation can therefore be a means of increasing both the lifespan and healthspan. In this review, accumulation of glycation products during aging is presented, pathophysiological effects of glycation are discussed and ways of attenuation of the effects of glycation are described, concentrating on prevention of glycation. The effects of glycation and glycation inhibitors on the course of selected age-related diseases, such as Alzheimer's disease, Parkinson's disease and cataract are also reviewed.

Keywords: Aging; Alzheimer’s disease; Cataract; Glycation; Glycation inhibitors; Parkinson’s disease.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / metabolism*
  • Aging / pathology
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology
  • Animals
  • Cataract / metabolism*
  • Cataract / pathology
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / pathology
  • Glycation End Products, Advanced / metabolism*
  • Humans
  • Parkinson Disease / metabolism*
  • Parkinson Disease / pathology

Substances

  • Glycation End Products, Advanced